Well-differentiated neuroendocrine tumors (NETs) account for ~80% of all NENs, have a rather indolent clinical behavior, as compared to their exocrine counterparts, and are associated with a good to moderate prognosis depending on primary tumor site, proliferative index (ki67 or mitotic index) and tumor stage. This evidence concerns the gene MKI67 and neoplasm.